NO20085418L - Langvarig, 24-timers tarmadministrering av levodopa/karbidopa - Google Patents
Langvarig, 24-timers tarmadministrering av levodopa/karbidopaInfo
- Publication number
- NO20085418L NO20085418L NO20085418A NO20085418A NO20085418L NO 20085418 L NO20085418 L NO 20085418L NO 20085418 A NO20085418 A NO 20085418A NO 20085418 A NO20085418 A NO 20085418A NO 20085418 L NO20085418 L NO 20085418L
- Authority
- NO
- Norway
- Prior art keywords
- levodopa
- carbidopa
- hour
- term
- long
- Prior art date
Links
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 title 1
- 230000007774 longterm Effects 0.000 title 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 229960004205 carbidopa Drugs 0.000 abstract 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80988906P | 2006-05-31 | 2006-05-31 | |
| PCT/EP2007/055275 WO2007138086A1 (en) | 2006-05-31 | 2007-05-31 | Long term 24 hour intestinal administration of levodopa/carbidopa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20085418L true NO20085418L (no) | 2009-02-26 |
Family
ID=38434843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20085418A NO20085418L (no) | 2006-05-31 | 2008-12-30 | Langvarig, 24-timers tarmadministrering av levodopa/karbidopa |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080051459A1 (ko) |
| EP (1) | EP2063865A1 (ko) |
| JP (1) | JP2009543761A (ko) |
| KR (1) | KR20090057349A (ko) |
| CN (1) | CN101636145B (ko) |
| AU (1) | AU2007267135B2 (ko) |
| BR (1) | BRPI0711882A2 (ko) |
| CA (1) | CA2653683A1 (ko) |
| HK (1) | HK1137931A1 (ko) |
| IL (1) | IL195599A0 (ko) |
| MX (1) | MX2008015339A (ko) |
| NO (1) | NO20085418L (ko) |
| RU (1) | RU2484815C2 (ko) |
| UA (1) | UA95954C2 (ko) |
| WO (1) | WO2007138086A1 (ko) |
| ZA (1) | ZA200810834B (ko) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5466179B2 (ja) * | 2008-02-06 | 2014-04-09 | ウォックハート リサーチ センター | 生物学的利用能が改善されたエンタカポン、レボドパ及びカルビドパの医薬組成物 |
| MX364974B (es) * | 2009-05-19 | 2019-05-16 | Neuroderm Ltd | Composiciones para la administracion continua de inhibidores de dopa descarboxilasa. |
| WO2012066538A1 (en) | 2010-11-15 | 2012-05-24 | Neuroderm Ltd | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
| EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| EP2653179B1 (en) | 2012-04-17 | 2019-07-10 | Micrel Medical Devices S.A. | System for calculating and administering a drug to a patient with Parkinson's disease |
| EP3456315A1 (en) | 2012-06-05 | 2019-03-20 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| RS65060B1 (sr) | 2014-03-13 | 2024-02-29 | Neuroderm Ltd | Sastavi inhibitora dopa dekarboksilaze |
| JP6622310B2 (ja) | 2014-09-04 | 2019-12-18 | ロブソル・ファーマシューティカルズ・アクチボラグＬｏｂｓｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｂｏｌａｇ | レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法 |
| AU2015335941B2 (en) * | 2014-10-21 | 2021-04-01 | Abbvie Inc. | Carbidopa and L-dopa prodrugs and their use to treat Parkinson's disease |
| MA41377A (fr) * | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| WO2016179540A1 (en) | 2015-05-06 | 2016-11-10 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| US10555922B2 (en) | 2015-09-04 | 2020-02-11 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| JP2019523249A (ja) * | 2016-07-20 | 2019-08-22 | アッヴィ・インコーポレイテッド | レボドパ及びカルビドパ腸管ゲル、並びに使用方法 |
| WO2018034626A1 (en) | 2016-08-18 | 2018-02-22 | İlko İlaç Sanayi Ve Ticaret Anonim Şirketi | Antiparkinson tablet formulation with improved dissolution profile |
| US11844860B2 (en) | 2018-03-02 | 2023-12-19 | Chiesi Farmaceutici S.P.A. | Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa |
| WO2019182506A1 (en) | 2018-03-23 | 2019-09-26 | Lobsor Pharmaceuticals Aktiebolag | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
| WO2019191353A1 (en) * | 2018-03-29 | 2019-10-03 | Riverside Pharmaceuticals Corporation | Levodopa fractionated dose composition and use |
| US11389398B2 (en) | 2019-05-14 | 2022-07-19 | Clexio Biosciences Ltd. | Gastroretentive treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| WO2023126945A1 (en) * | 2022-01-03 | 2023-07-06 | Neuroderm, Ltd. | Methods and compositions for treating parkinson's disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9203594D0 (sv) * | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| US6166081A (en) * | 1997-10-09 | 2000-12-26 | Kushnir; Moshe | Methods and apparatus for treatment of Parkinson's disease |
| EA200300046A1 (ru) * | 2000-06-23 | 2003-10-30 | Тева Фармасьютикал Индастриес Лтд. | Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию |
| FR2829027A1 (fr) * | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
| US20060013875A1 (en) * | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| ITMI20030827A1 (it) * | 2003-04-18 | 2004-10-19 | Unihart Corp | Composizione farmaceutica contenente l'associazione levodopa/carbidopa. |
| AU2004285436C1 (en) * | 2003-10-20 | 2009-07-16 | Teva Pharmaceutical Industries Ltd. | Composition and dosage form for sustained effect of levodopa |
| NZ551511A (en) * | 2004-06-04 | 2010-09-30 | Xenoport Inc | Levodopa prodrugs, and compositions and uses thereof |
| WO2006044202A2 (en) * | 2004-10-19 | 2006-04-27 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid |
| US20070003621A1 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| WO2007056570A2 (en) * | 2005-11-07 | 2007-05-18 | Teva Pharmaceutical Industries Ltd. | Levodopa compositions |
-
2007
- 2007-05-31 BR BRPI0711882-1A patent/BRPI0711882A2/pt not_active IP Right Cessation
- 2007-05-31 AU AU2007267135A patent/AU2007267135B2/en active Active
- 2007-05-31 KR KR1020087031660A patent/KR20090057349A/ko not_active Application Discontinuation
- 2007-05-31 CN CN200780019726.8A patent/CN101636145B/zh active Active
- 2007-05-31 JP JP2009512591A patent/JP2009543761A/ja not_active Withdrawn
- 2007-05-31 WO PCT/EP2007/055275 patent/WO2007138086A1/en active Application Filing
- 2007-05-31 US US11/756,297 patent/US20080051459A1/en not_active Abandoned
- 2007-05-31 MX MX2008015339A patent/MX2008015339A/es active IP Right Grant
- 2007-05-31 ZA ZA200810834A patent/ZA200810834B/xx unknown
- 2007-05-31 EP EP07729688A patent/EP2063865A1/en not_active Withdrawn
- 2007-05-31 RU RU2008150776/15A patent/RU2484815C2/ru active
- 2007-05-31 CA CA002653683A patent/CA2653683A1/en not_active Withdrawn
- 2007-05-31 UA UAA200814421A patent/UA95954C2/ru unknown
-
2008
- 2008-11-30 IL IL195599A patent/IL195599A0/en unknown
- 2008-12-30 NO NO20085418A patent/NO20085418L/no not_active Application Discontinuation
-
2010
- 2010-04-21 HK HK10103896.7A patent/HK1137931A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101636145A (zh) | 2010-01-27 |
| BRPI0711882A2 (pt) | 2012-01-10 |
| AU2007267135B2 (en) | 2013-03-07 |
| JP2009543761A (ja) | 2009-12-10 |
| RU2008150776A (ru) | 2010-07-10 |
| US20080051459A1 (en) | 2008-02-28 |
| EP2063865A1 (en) | 2009-06-03 |
| UA95954C2 (ru) | 2011-09-26 |
| HK1137931A1 (en) | 2010-08-13 |
| MX2008015339A (es) | 2008-12-16 |
| CN101636145B (zh) | 2014-04-23 |
| ZA200810834B (en) | 2010-03-31 |
| AU2007267135A1 (en) | 2007-12-06 |
| RU2484815C2 (ru) | 2013-06-20 |
| WO2007138086A1 (en) | 2007-12-06 |
| IL195599A0 (en) | 2009-09-01 |
| CA2653683A1 (en) | 2007-12-06 |
| KR20090057349A (ko) | 2009-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20085418L (no) | Langvarig, 24-timers tarmadministrering av levodopa/karbidopa | |
| CY1118672T1 (el) | Συνθεσεις ταπενταδολης | |
| UA94390C2 (ru) | Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких | |
| DK1970059T3 (da) | Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser | |
| TW200505423A (en) | Combination, kit and pharmaceutical composition for treatment of parkinson's disease | |
| NO20090591L (no) | Metabolisme modulatorer samt behandling av lidelser relatert dertil | |
| NO20080088L (no) | Sterkt biotilgjengelige orale forsinkede frigjoringsformer av O-desmetylvenlafaksin | |
| HK1085140A1 (en) | Pharmaceutical compositions and method of using levodopa and carbidopa | |
| EA200700851A1 (ru) | Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения | |
| NZ593199A (en) | Milnacipran for the long-term treatment of fybromyalgia syndrome | |
| EA201000855A1 (ru) | Способ и средства для достижения бронхиальной релаксации | |
| NO20082636L (no) | Anvendelse av DHA og ARA for fremstilling av en sammensetning for forebygging eller behandling av fedme | |
| MX2009004616A (es) | Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente. | |
| NO20064515L (no) | Farmasoytisk preparat med kontrollert frigivelse av tolperison for oral administrering | |
| MX2007004111A (es) | Sal y formas cristalinas de la misma de un farmaco. | |
| NO20073830L (no) | Medikamenter for behandling eller forebygging av fibrotiske sykdommer | |
| DK1784173T3 (da) | Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater | |
| SE0400184D0 (sv) | New therapeutical use | |
| CY1111588T1 (el) | Υποκατεστημενα καρβοξαμιδια ως ανταγωνιστες μεταβολοτροπου υποδοχεα ομαδας ι | |
| HK1131340A1 (en) | Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance | |
| MX2010007527A (es) | Composicion farmaceutica, uso del derivado 2-iminopirrolidina para la produccion de la composicion farmaceutica y kit para el tratamiento o mejora de enfermedaes cardiacas. | |
| ITFI20080024A1 (it) | Metodo per la correzione incruenta dell'ipercifosi dorsale e tutore ortopedico per la sua attuazione. | |
| UA46213U (ru) | Способ комплексного ортодонтического лечения зубочелюстных аномалий | |
| NO20073942L (no) | Farmasoytiske sammensetninger for behandling av sykdommer assosiert med NF-KB-aktivitet | |
| UA36750U (ru) | Способ лечения лейкоплакии слизистой оболочки полости рта |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |